TrialHaematologica2022

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.

Cyrille Touzeau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.